Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology
Rhea-AI Summary
Stereotaxis (NYSE: STXS) announced that Oulu University Hospital in Finland has successfully implemented and begun treating patients with the advanced Genesis Robotic Magnetic Navigation (RMN) System. The hospital, which has previously treated over 2,000 patients with earlier versions of the technology, is now enhancing its arrhythmia care capabilities in northern Finland.
The Genesis System represents a significant advancement in Robotic Magnetic Navigation technology for cardiac ablation procedures, offering robotic precision and safety in treating arrhythmias. This condition, affecting tens of millions globally, can lead to increased risks of stroke, heart failure, and sudden cardiac arrest if left untreated.
Dr. Jarkko Magga, Cardiac Electrophysiologist at Oulu University, highlighted that robotic technology has been important to their team's ability to provide superior care for complex cardiac arrhythmias over the past 15 years. The hospital's adoption of the Genesis System demonstrates their commitment to maintaining high-quality patient care standards.
Positive
- Successful implementation of advanced Genesis RMN System in a major hospital
- Expansion into Finnish market with established partner (2,000+ previous treatments)
- Technology has been used to treat over 150,000 patients globally
Negative
- None.
Insights
The installation of the Genesis Robotic System at Oulu University Hospital represents an incremental business development rather than a material financial catalyst. While this deployment maintains Stereotaxis's presence in the Nordic market and showcases continued adoption of their latest technology, the revenue impact from a single installation is modest relative to STXS's
The strategic value lies in the hospital's extensive experience with over 2,000 previous robotic procedures, which validates the technology's long-term clinical utility. However, this is primarily a replacement/upgrade sale rather than expansion into a new account. The Nordic healthcare market, while sophisticated, represents a relatively small addressable market compared to major regions like the US, Western Europe and Asia.
For investors, this news reinforces STXS's competitive position in robotic cardiac ablation but doesn't materially change the company's near-term growth trajectory or financial outlook. The real value drivers remain broader commercial adoption in major markets and the development of next-generation technologies.
The Genesis System deployment highlights Stereotaxis's technological evolution in robotic magnetic navigation (RMN) for cardiac procedures. The system's key advantages include enhanced precision during catheter manipulation and improved safety profiles compared to manual approaches - critical factors for complex arrhythmia cases.
Particularly noteworthy is Oulu's 15-year track record with RMN technology and treatment of over 2,000 patients, demonstrating both the durability of the platform and physician loyalty to the technology. The upgrade to Genesis indicates confidence in Stereotaxis's latest innovations and suggests strong clinical outcomes with their previous systems.
From a medical technology perspective, this installation reinforces the growing role of robotics in complex cardiac procedures, especially for treating the tens of millions affected by arrhythmias globally. However, the broader challenge for Stereotaxis remains accelerating adoption rates and competing with traditional manual approaches that dominate the market despite their limitations.
ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.
Oulu University Hospital has significant experience pioneering the use of robotic technologies for the treatment of heart arrhythmias, having treated over 2,000 patients with original versions of the technology. The implementation of the latest Genesis System introduces significant advances in Robotic Magnetic Navigation technology to the northern regions of Finland. Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmias may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.
“For 15 years, advanced robotic technology has been essential to our team, allowing us to provide superior patient care for patients with complex cardiac arrhythmias,” said Dr. Jarkko Magga, Cardiac Electrophysiologist at Oulu University. “We are pleased to continue to provide the highest quality patient care with the precision and stability offered by the more advanced Genesis System.”
“We are proud to enhance and expand our partnership with Oulu University to ensure patients in Finland have access to leading cardiac care,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to continuing to support their successful and impactful robotic heart rhythm practice.”
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and statements relating to our recent acquisition of APT, including any benefits expected from the acquisition, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly Peery
Chief Financial Officer
314-678-6100
Investors@Stereotaxis.com
FAQ
What is the significance of Oulu University Hospital implementing Stereotaxis (STXS) Genesis System?
How many patients have been treated with Stereotaxis (STXS) technology globally?
What medical conditions does the Stereotaxis (STXS) Genesis System treat?
How long has Oulu University Hospital been using Stereotaxis (STXS) robotic technology?
